Trumpeting its psoriasis candidate bimekizumab’s superiority in the Be Radiant head-to-head trial against Novartis’s Cosentyx today has gained UCB little: with no data released there is no way to gauge exactly how well the IL-17A and IL-17F inhibitor stacks up against the variety of MAbs already occupying this space. That said, efficacy data from the placebo-controlled Be Ready trial, released in June, were pretty spectacular, so if the Be Radiant results come in at a similar level bimekizumb could shake up the market. The primary endpoint of te Be Radiant study, Pasi 100 response at four months, differs from the claims other psoriasis MAbs make on their labels, meaning that comparisons against anything other than Cosentyx will rely on secondary endpoints, including 48-week data, once UCB releases the actual figures. Given the impressive Be Ready data, sellside consensus sales forecasts for bimekizumab, as calculated by EvaluatePharma, seem rather low at $931m in 2026.
|Comparison of phase III data on selected IL-23s and IL-17s in psoriasis|
|Company||Abbvie||Johnson & Johnson||Novartis||UCB|
|Therapy||Skyrizi (IL-23)||Tremfya (IL-23)||Cosentyx
|PAI in PGA of clear or almost clear (%)||80||79||78||76||63||59||91|
|PAI in Pasi 90 (%)||70||73||70||68||58||52||90|
|PAI = placebo-adjusted improvement. PGA = physician’s global assessment. Source: drug labels; Lilly and UCB press releases.|